Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in controlling chronic cough [5] Public Offering Details - Trevi Therapeutics has initiated an underwritten public offering of $100,000,000 of its common stock, with an additional option for underwriters to purchase up to $15,000,000 more [1] - The offering is being managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor as joint book-running managers [2] - The shares are offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3] Offering Conditions - The completion of the offering is subject to market and other conditions, with no assurance on the timing or terms of the offering [2] - A preliminary prospectus supplement detailing the terms of the offering is expected to be filed with the SEC [3]